|Print Page Close Window|
AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The company is focused on developing and commercializing its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for Renal Cell Carcinoma and other cancers. AVEO is leveraging multiple partnerships to develop and commercialize tivozanib in non-oncologic indications worldwide and oncology indications outside of North America, as well as to progress its pipeline of novel therapeutic candidates in cancer and cachexia (wasting syndrome).
02/23/17AVEO Announces TIVO-3 Passes The First Safety Monitoring Committee Safety ReviewRead More
02/09/17AVEO Announces Clinical and Regulatory Updates for TivozanibRead More
02/06/17AVEO to Present at the 19th Annual BIO CEO & Investor ConferenceRead More
02/13/17 8:30 a.m. ET AVEO Oncology at the 19th Annual BIO CEO & Investor Conference
Corporate PresentationAVEO Oncology Corporate Presentation